NCT05411133View on ClinicalTrials.gov

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions
Gastrointestinal CancerCholangiocarcinomaLiver CancerColorectal AdenocarcinomaPancreatic CancerGastric CancerEsophageal AdenocarcinomaGastroesophageal JunctionGastrointestinal Neuroendocrine Tumors
Interventions
DRUG

Cabotamig (ARB202)

Cabotamig (ARB202), Atezolizumab

Trial Locations (3)

Unknown

RECRUITING

Southern Oncology Clinical Research Unit, Adelaide

RECRUITING

St George Private Hospital, Sydney

RECRUITING

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Arbele Pty Ltd

INDUSTRY